SCHEMBL4002382

SCHEMBL4002382

O=C(OCO)N1CCC(c2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.58
SLC18A3 Q16572 2/20 0.52
BRD4 O60885 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
ALDH1A1 P00352 4/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
SIGMAR1 Q99720 1/20 0.51
POLB P06746 1/20 0.51
KCNH2 Q12809 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4035554 0.85 SMN1; SMN2 (0.72) CHRM4SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL4392358 0.84 PRMT5 (0.56) ALDH1A1POLBL3MBTL1GAAMAPT
SCHEMBL5451965 0.84 CHRM4 (0.55) CHRM4SLC18A3BRD4SMN1; SMN2ALDH1A1
SCHEMBL21159622 0.82 BRD4 (0.61) CHRM4SLC18A3BRD4SMN1; SMN2ALDH1A1
SCHEMBL8922008 0.81 CHRM4 (0.59) CHRM4SLC18A3BRD4SMN1; SMN2ALDH1A1
SCHEMBL31073550 0.81 KCNH2 (0.56) CHRM4SLC18A3BRD4SMN1; SMN2ALDH1A1
SCHEMBL28171449 0.81 KCNH2 (0.52) CHRM4SLC18A3SMN1; SMN2ALDH1A1RAB9A
SCHEMBL5460480 0.80 FAAH (0.55) CHRM4SLC18A3BRD4SMN1; SMN2ALDH1A1
SCHEMBL12745808 0.79 GAA (0.69) SMN1; SMN2ALDH1A1RAB9ANPC1KCNH2
SCHEMBL17787758 0.79 ALDH1A1 (0.59) SLC18A3SMN1; SMN2ALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009009411-A1 SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-15 WO disclosed